-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3453 The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Hematology Disease Topics & Pathways:
Research, Biological therapies, epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, Therapies, registries, Transplantation
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Yasmine Kadri, MD1, Michelle Phan, B.Sc.2*, Nadia Bambace, MD3*, Léa Bernard, MD3*, Sandra Cohen, MD3*, Jean-Sébastien Delisle, MD, PhD3, Thomas L. Kiss, MD3, Sylvia Lachance, MD pour tous, MD, PhD pour JSD et GS3*, Denis-Claude Roy, MD4, Jean Roy, MD3*, Guy Sauvageau, MD, PhD3, Olivier Veilleux, MD3 and Imran Ahmad, MD3*

1Hôpital Maisonneuve-Rosemont, Laval, QC, Canada
2Département de Pharmacologie & Physiologie, Université de Montréal, Montreal, QC, Canada
3Département de Médecine, Université de Montréal, Montreal, QC, Canada
4Department of Medicine, Université de Montréal, Montreal, QC, Canada

Background: Using EBMT registry data, the DRSS has been proposed to predict relapse risk after allogeneic hematopoietic cell transplantation (HCT) across disease subtypes and remission states ordered in 55 categories and 5 risk levels (Shouval R et al. Lancet Haematol. 2021). For acute myeloid leukemia (AML) the DRSS combines ELN risk group, remission rank, and de novo vs. secondary AML in 19 categories and for myelodysplastic syndrome (MDS) it includes 5 categories.

Purpose: We sought to determine the reproducibility of the DRSS in a cohort of subjects transplanted for AML and MSD.

Methodology: Data from a single-center cohort of adult AML patients transplanted between 01/07/2015 and 30/06/2020 was analyzed retrospectively. Baseline characteristics and outcomes were extracted and Fine-Gray regression was used to determine the association between cumulative incidence of relapse (CIR) and patient, disease, and transplant characteristics. Model selection techniques were used to select the least number of significant predictors of CIR.

Results: In this cohort of 125 patients, median follow-up was 2.8 years (interquartile range: 0.9-3.2) and CIR was 26 % at 4 years (95% confidence interval: 18-35). The study of the association between CIR and patient age >60 years, donor type (related matched, haploidentical, matched unrelated), regimen intensity, secondary disease, graft source (peripheral blood, bone marrow) and DRSS. Risk categories for DRSS was divided into 3 groups with CIR at 4 years of 18% (confidence interval [IC] 8-30) for low risk, CIR of 32% (IC19-46) for intermediate 1 and 2, and CIR of 40% (IC 17-63) for high and very high group. Univariate graphic representation of CIR according to DRSS is shown in figure 1.

Conclusions: In adults with AML and MDS, cumulative incidence of relapse after allogeneic HCT can be predicted by DRSS across all donor types and age groups.

Disclosures: Roy: Kiadis Pharma: Consultancy, Honoraria; Knight Therapeutics: Consultancy; Pfizer: Speakers Bureau. Sauvageau: ExCellThera: Consultancy, Current Employment, Current equity holder in private company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; BMS: Research Funding. Veilleux: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite-Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH